Profile
Sector:
HealthcareIndustry:
Diagnostics & ResearchCountry:
United StatesIPO:
21 June 1991Website:
http://www.idexx.comNext earnings report:
05 February 2025Last dividends:
N/ANext dividends:
N/APrice
pre-market | 30 min agoDividend
Analysts recommendations
Institutional Ownership
IDXX Latest News
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a leading company in pet healthcare innovation, has announced that Brian McKeon will retire on June 1, 2025. Andrew Emerson, who is currently the Senior Vice President of Finance for the Corporate and Companion Animal Group, will take over as Executive Vice President, Chief Financial Officer, and Treasurer starting March 1, 2025. Until his retirement, Mr. McKeon will continue to work as EVP and Special Advisor to the company.
I maintain a 'Sell' rating on IDEXX because of low clinical visits and demand in the U.S., setting a one-year price target of $400 per share. The company's Q3 results revealed a 2.1% drop in same-store clinical visits, which fell short of market expectations, prompting a reduction in revenue growth forecasts for FY24. Although IDEXX has strong recurring revenue and high retention rates, ongoing economic issues and high-interest rates are likely to affect its business growth.
IDEXX Laboratories, Inc. (NASDAQ:IDXX) will hold its Q3 2024 Earnings Conference Call on October 31, 2024, at 8:30 AM ET. The call will feature company representatives, including CFO Brian McKeon and President and CEO Jay Mazelsky, along with participants from various financial institutions. Please note that this conference is being recorded.
WESTBROOK, Maine--(BUSINESS WIRE)--In the 2024 Growth and Financial Performance Outlook section, the second paragraph's second sentence should state: At the midpoint, the expected full-year comparable operating profit margin growth of 30 - 60 basis points accounts for a roughly 40 basis point negative impact due to a customer contract resolution payment from the first quarter of 2023. (instead of: At midpoint, projected full year comparable operating profit margin expansion of 70 - 100 basis points inclu.)
Idexx Laboratories (IDXX) reported quarterly earnings of $2.80 per share, which is higher than the Zacks Consensus Estimate of $2.69 per share. This is an increase compared to last year's earnings of $2.53 per share.
On Thursday, IDEXX Laboratories reduced its yearly revenue prediction for the third time because they are noticing a decline in the number of pet owners visiting veterinary clinics. The company specializes in diagnostic equipment for animal health.
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a worldwide leader in pet healthcare advancements, has shared its results for the third quarter. The company reported revenues of $976 million for the third quarter of 2024, marking a 7% increase overall and a 6% increase organically, mainly due to a 7% growth in the Companion Animal Group (CAG) and a 13% rise in Water revenue. Additionally, CAG Diagnostics saw a recurring revenue growth of 7%.
Assess the anticipated performance of Idexx (IDXX) for the quarter that ended in September 2024. Instead of just focusing on the usual Wall Street revenue and profit predictions, take a closer look at some important metrics for a deeper understanding.
IDEXX Laboratories is likely to have performed well in the third quarter of 2024 due to effective implementation of its key strategies.
IDEXX has seen a decrease in its full-year organic revenue growth because of fewer clinical visits in the U.S. Ongoing issues with consumer confidence and staffing could keep affecting these visits for a while. Although the introduction of new menu options for the Catalyst platform might boost the diagnostic business, the stock is still considered overvalued.
What type of business is IDEXX Laboratories?
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services for veterinary, livestock, poultry, dairy industry, and water testing worldwide. The company provides veterinary diagnostic products; veterinary drugs, reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians. The company also offers diagnostic and health products for livestock, poultry, and dairy industry; products for water testing for various microbiological contaminants. IDEXX Laboratories, Inc. was founded in 1983 and is headquartered in Westbrook, Maine.
What sector is IDEXX Laboratories in?
IDEXX Laboratories is in the Healthcare sector
What industry is IDEXX Laboratories in?
IDEXX Laboratories is in the Diagnostics & Research industry
What country is IDEXX Laboratories from?
IDEXX Laboratories is headquartered in United States
When did IDEXX Laboratories go public?
IDEXX Laboratories initial public offering (IPO) was on 21 June 1991
What is IDEXX Laboratories website?
https://www.idexx.com
Is IDEXX Laboratories in the S&P 500?
Yes, IDEXX Laboratories is included in the S&P 500 index
Is IDEXX Laboratories in the NASDAQ 100?
Yes, IDEXX Laboratories is included in the NASDAQ 100 index
Is IDEXX Laboratories in the Dow Jones?
No, IDEXX Laboratories is not included in the Dow Jones index
When was IDEXX Laboratories the previous earnings report?
No data
When does IDEXX Laboratories earnings report?
The next expected earnings date for IDEXX Laboratories is 05 February 2025